Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Hepatic arginase deficiency fosters dysmyelination during postnatal CNS development
Xiao-Bo Liu, Jillian R. Haney, Gloria Cantero, Jenna R. Lambert, Marcos Otero-Garcia, Brian Truong, Andrea Gropman, Inma Cobos, Stephen D. Cederbaum, Gerald S. Lipshutz
Xiao-Bo Liu, Jillian R. Haney, Gloria Cantero, Jenna R. Lambert, Marcos Otero-Garcia, Brian Truong, Andrea Gropman, Inma Cobos, Stephen D. Cederbaum, Gerald S. Lipshutz
View: Text | PDF
Research Article Neuroscience

Hepatic arginase deficiency fosters dysmyelination during postnatal CNS development

  • Text
  • PDF
Abstract

Deficiency of arginase is associated with hyperargininemia, and prominent features include spastic diplegia/tetraplegia, clonus, and hyperreflexia; loss of ambulation, intellectual disability and progressive neurological decline are other signs. To gain greater insight into the unique neuromotor features, we performed gene expression profiling of the motor cortex of a murine model of the disorder. Coexpression network analysis suggested an abnormality with myelination, which was supported by limited existing human data. Utilizing electron microscopy, marked dysmyelination was detected in 2-week-old homozygous Arg1-KO mice. The corticospinal tract was found to be adversely affected, supporting dysmyelination as the cause of the unique neuromotor features and implicating oligodendrocyte impairment in a deficiency of hepatic Arg1. Following neonatal hepatic gene therapy to express Arg1, the subcortical white matter, pyramidal tract, and corticospinal tract all showed a remarkable recovery in terms of myelinated axon density and ultrastructural integrity with active wrapping of axons by nearby oligodendrocyte processes. These findings support the following conclusions: arginase deficiency is a leukodystrophy affecting the brain and spinal cord while sparing the peripheral nervous system, and neonatal AAV hepatic gene therapy can rescue the defects associated with myelinated axons, strongly implicating the functional recovery of oligodendrocytes after restoration of hepatic arginase activity.

Authors

Xiao-Bo Liu, Jillian R. Haney, Gloria Cantero, Jenna R. Lambert, Marcos Otero-Garcia, Brian Truong, Andrea Gropman, Inma Cobos, Stephen D. Cederbaum, Gerald S. Lipshutz

×

Figure 2

Microarray expression studies of the brain in arginase deficiency reveal evidence of dysregulation of myelinating oligodendrocytes.

Options: View larger image (or click on image) Download as PowerPoint
Microarray expression studies of the brain in arginase deficiency reveal...
(A) Arg1 graph: P values for Arg1 (adjusted P value from Tukey HSD test from ANOVA [P = 5 × 10−13] of Arg1 normalized expression by genotype/treatment) are plotted for WT, homozygous Arg1-KO, Arg1 heterozygote (Het), and AAV-treated hepatic Arg1-expressing mice (treated KO) at P14 (n = 6 per group). Individual samples are also plotted. Overexpression of Arg1 indicates the upregulation of a faulty transcript, demonstrating that regulatory mechanisms are activated to produce Arg1 in the CNS in the KO, Het, and treated KO groups. (B) ARG1 in Allen Developing Human Brain Atlas: BrainSpan data was acquired (http://www.brainspan.org/static/download.html) and RNA-Seq (reads per kilobase of transcript, per million mapped reads; RPKM) Gencode v.10 summarized to genes. Gray shading indicates 95% CI. Evident expression of ARG1 in the cortical and subcortical regions of the human brain is present with upregulation around birth. (C) Myelinating oligodendrocyte (MO) dysregulated module graph. This module contains 374 coexpressed genes that share a cell type expression signature with MOs. The first principal component of expression is plotted on the y axis. P values for this PC1 (adjusted P value from Tukey HSD test from ANOVA of MO dysregulated genes PC1 by genotype/treatment [P = 0.024]) plotted above graph. Individual samples are also plotted. Cell type enrichment (D) and gene ontology (E) for MO module. Cell type markers for MOs that were specific for MOs with P < 0.01 (pSI method), utilizing neural cell type specific gene expression (61) were used for cell type enrichment analysis. Cell type enrichment P values were calculated with overrepresentation analysis. Gene ontology overlap was established with the gProfileR method, which implements overrepresentation analysis to obtain enrichment P values. Bonferroni adjusted P values plotted for both.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts